Everspin's Growth Ex-AI Hype, But Defense Conversion Still Needs Auditable Proof

What happened

After the AI-driven spike and subsequent correction in mid-2026, Everspin reported record Q3 2026 revenue of $20.6 million, up 47% YoY, with robust product sales and a significant defense contract boosting licensing and services. Seeking Alpha now rates the stock a buy with 17% FY2027 upside, arguing growth is driven by data center and RAID storage demand rather than direct AI exposure. However, the earlier DeepValue master report set a WAIT rating, requiring proof that the $40 million Amentum defense subcontract would translate into measurable contract assets/liabilities and cash collections, and that higher-density xSPI MRAM would ship in volume. The new article does not independently verify these specific financial disclosures, and third-party bullishness must be tempered by the company's history of headline-driven volatility and insider selling. The positive Q3 print is a step in the right direction, but the core thesis breaker—auditable defense milestone conversion—remains only partially validated by the article's mention of licensing and services growth.

Implication

Investors should not chase the Seeking Alpha buy rating without verifying Q3 10-Q details showing Amentum-related contract assets/liabilities, milestone billings, or over-time revenue share, as the master report set that as the prerequisite for re-rating. The record revenue and licensing/services boost are encouraging, but the company's balance sheet still faces cash obligations from Microchip reimbursements and litigation costs, and distributor concentration remains high at 90%. The next catalyst is the Q4 or FY2026 filing, which must show continued defense milestone conversion and tangible xSPI volume shipments to sustain the growth narrative. If those signals appear, the WAIT rating could shift to BUY with a target near the bull-case $35, but if they are absent, the stock may compress toward the bear-case $15. Risk management suggests waiting for that auditable evidence rather than relying on a single third-party article, especially given recent insider selling and a pending ITC investigation.

Thesis delta

The thesis shifts from full skepticism to cautious optimism, as Q3 results show strong revenue growth and licensing/services gains that may reflect initial Amentum milestone recognition. However, without direct access to the 10-Q details, we cannot confirm contract asset/liability buildup or xSPI mix shift, so the WAIT rating remains but with a positive bias contingent on Q4 confirmation. The core requirement for auditable defense conversion is unchanged; only the probability of near-term confirmation has improved slightly.